Skip to main content
. 2013 Feb 18;34(4):561–569. doi: 10.1038/aps.2012.173

Table 2. Some potential risk sites found in the human genome.

Gene Hits Brief discription
Acyp2 GGGGTTCCCCCTTGTTCTTGGGTCGGGATGCAGTCCAGGAACCCC Acylphosphatase 2, muscle type
Akr1b1 GGGGTGCCCAGATTTTTCTCCCGAGTTCCAGACCCAGGGCACCCC Aldo-ketoreductase family 1, member B1
Dusp4 GGGGTTCCTTATCCTTCCCACCCGCCCTCAAACCCAGGAACCCC Dual specificity phosphatase 4
Ptpn5 GGGGTGCCCCCATGCGGCAAGGTCCGAGATGTGCCGGCACCCC Protein tyrosine phosphatase, non-receptor
Fli1 GGGGTTCCTTTTACAGAGACAATTGTTGGGTCAAGAAGGAACCCC Friend leukemia virus integration 1
Gpt2 GGGGTTCCCTTGAACATGCGTAGGCTGGAACCCC Glutamic pyruvate transaminase (alanine aminotransferase)
Slc7a5 GGGGTGCCTTGGGGGCAGTGCATTGGAGGAACCCC Solute carrier family 7 (cationic amino acid transporter, y+ system), member 5
Dhdh GGGGTTCCAGGTAGAGGTTGAAAGGACCAAGGAACCCC Dihydrodiol dehydrogenase (dimeric)
Phf2 CCCCAAGGAGCCCAGGACTTGGCCTTGGGG PHD finger protein 2
Igf1r CCCCAAGGAAAGCATATCATAAACAAGTTTTCCCTTGGGG Insulin-like growth factor 1 receptor
Wwp2 CCCCAAGGGTACAGAACAGTGTCACCTTTGCCGTGGGG WW domain containing E3 ubiquitin protein ligase 2
Flj39501 CCCCAAGGTCACATTAATTGAGCGATCCGTGGGG Cytochrome P450, family 2, subfamily E, polypeptide 2 homolog
Plcb1 CCCCAAGGCTCCATGTCTGAACATCATCACCTTGGGG Phospholipase C, beta 1 (phosphoinositide -specific)
Flj10945 CCCCAAGGGCACACGTAGAAGCAGAGTTCCTTGGGG Hypothetical protein FLJ10945
Stk11* CCCCAGGGAGGCGGGGCTTTTGTGCAGAAATGTAGGGTTGGGG This gene encodes a tumor suppressor
Leng4 CCCCAGTTGAGAAGCACTTGTCTAAACACTGGGG This gene is malignant cell expression-enhanced gene/
    Tumor progression -enhanced gene
Cyp2b6 CCCCACTATTTATTTTTGTAGAGATGTGTTTGGGG Cytochrome P450, family 2, subfamily
Ryr1 CCCCAAGGTCCGGGTTGGGGACCTTGTGCTGGGG Ryanodine receptor 1 (skeletal); Multi-process involved
Icam1 CCCCAGCCGAGAATTTCTCTTTGCGTCCTTCCTACTTTGGGG Intercellular adhesion molecule 1 (CD54); Multi-process involved

* Hit in STK11 has a relatively lower score but it has a similar motif to the wide type attPsites. So does the last four sites, LENG4, CYP2B6, RYR1, and ICAM1.